<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190202042596N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-09</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Acupuncture for treatment of abnormal uterine bleeding</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of acupuncture on regulating the menstrual cycle in the patients with abnormal uterine bleeding</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>76</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57612</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly divided into intervention and control groups using the random block method using the website sealedenvelop.com. Allocation concealment will be done using opaque, sealed and numbered envelopes.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Abnormal uterine bleeding.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: 12 weekly acupuncture treatment sessions besides  routine drugs for example  progestogenic pills such as tab medroxyprogesterone for 10 days, 10 mg daily from the 14th day of the cycle, cyclic   tab combined estrogen-progesterone pills, non-steroidal anti-obesity drugs such as cap mefenamic acid 500 mg q 8 h and  cap tranexamic acid 500 mg q 8 h. Intervention 2: Control group: Routine Drugs  for example  progestogenic pills such as medroxyprogesterone, combined estrogen-progesterone pills, non-steroidal anti-obesity drugs and tranexamic acid.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on the main outcomes is shared

When:
The access period begins three months after the publication of the results

To whom:
Academic researchers

Conditions:
Using data to check the quality of analysis

Where to obtain:
Mahnaz Boroumand Rezazadeh
Department of Obstetrics and Gyneccology, Mashhad University of Medical Sciences

How to obtain:
one month after request

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahnaz Boroumand Rezazadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sanabad</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9138943662</zip>
        <telephone>+98 51 3842 1052</telephone>
        <email>boroumandrm@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahnaz Boroumand Rezazadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sanabad</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9138943662</zip>
        <telephone>+98 51 3842 1052</telephone>
        <email>boroumandrm@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Irregular menstrual cycle in the form of:                                                    1-Polymenorrhea (menstrual cycle time less than 21 r)                                        2-Oligomenorrhea (menstrual cycle duration more than 35 days) 3-Bleeding between cycles                                                                            4-Spotting before or after menopause                                                                                 5-hypermenorrhea (uterine bleeding more than 80 cc In each cycle, blood clot excretion more than 2 hours, the need to replace the night pad, severe uterine bleeding leading to anemia)                                           6-Absence of structural disorders justifying bleeding such as Fibroids, polyps, hyperplasia, cancer, adenomyosis, etc.                7-Consent to participate in the study and use of acupuncture        9-No Acupuncture Contraindications - Acupuncture Contraindications: Pregnancy, skin problems such as infection or inflammation at the site of acupuncture</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>1-Trauma                                                                                                        2-Drugs                                                                                                           3-Postpartum                                                                                                 4-Structural disorders such as fibroids, polyps, hyperplasia, cancer, adenomyosis, etc.                                                                       5-Failure to follow the course of treatment,                                                          6-Postmenopausal bleeding                                                                                 7-Vaginal bleeding due to pregnancy complications</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N93.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Abnormal uterine and vaginal bleeding, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: 12 weekly acupuncture treatment sessions besides  routine drugs for example  progestogenic pills such as tab medroxyprogesterone for 10 days, 10 mg daily from the 14th day of the cycle, cyclic   tab combined estrogen-progesterone pills, non-steroidal anti-obesity drugs such as cap mefenamic acid 500 mg q 8 h and  cap tranexamic acid 500 mg q 8 h</i_keyword>
      <i_keyword>Control group: Routine Drugs  for example  progestogenic pills such as medroxyprogesterone, combined estrogen-progesterone pills, non-steroidal anti-obesity drugs and tranexamic acid</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Length of menstrual cycle. Timepoint: The period of six months- The duration of the monthly menstrual cycle is checked before the intervention and immediately after the completion of the three-month course of acupuncture and drug treatment and three months after the end of the intervention. Method of measurement: Reassessment of signs &amp; symptoms.</prim_outcome>
      <prim_outcome>Duration of menstrual bleeding. Timepoint: The period of six months- The duration of the monthly menstrual bleeding is checked before the intervention and immediately after the completion of the three-month course of acupuncture and drug treatment and three months after the end of the intervention. Method of measurement: Reassessment of signs &amp; symptoms.</prim_outcome>
      <prim_outcome>Intensity of monthly bleeding. Timepoint: The period of six months- The intensity of monthly bleeding is checked before the intervention and immediately after the completion of the three-month course of acupuncture and drug treatment and three months after the end of the intervention. Method of measurement: Reassessment of signs &amp; symptoms.</prim_outcome>
      <prim_outcome>Frequency of menstrual habits. Timepoint: The period of six months- The frequency of menstrual habits is checked before the intervention and immediately after the completion of the three-month course of acupuncture and drug treatment and three months after the end of the intervention. Method of measurement: Reassessment of signs &amp; symptoms.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-09-18</approval_date>
        <contact_name>Ethics Committee of Mashhad Medical School</contact_name>
        <contact_address>Sanabad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
